Literature DB >> 7997057

Neurotransmitter receptor plasticity in aging.

N W Pedigo1.   

Abstract

Neurotransmitter receptor plasticity is an important part of the compensatory processes by which the central nervous system adapts to pathological insult, long-term exposure to drugs or neuronal loss with advanced age. Receptor plasticity can be manifest as changes in the number of receptors (i.e., up- or down-regulation), changes in expression of mRNA for discrete receptor proteins, or alterations in receptor coupling to signal transduction systems. Evidence exists for impaired plasticity of neurons in the aged brain, which results in decreased ability to adjust to changes in their environment. However, such data are highly dependent on the neurotransmitter examined, the stimulus for receptor regulation and the animal model chosen for study. For example, senescent rats show an age-related impairment of muscarinic receptor up- or down-regulation after long-term exposure to cholinergic drugs. Thus, young rats exposed to chronic (three weeks) intracerebroventricular infusions of methylatropine or oxotremorine exhibit compensatory changes in the density of muscarinic receptors in frontal cortex and hypothalamus. In contrast, 3H-QNB binding is unaltered in the same brain regions of identically treated senescent rats. Similar observations of impaired muscarinic receptor plasticity in senescent animals have been confirmed by other investigators. Age-related differences in coupling of brain muscarinic receptors to G-proteins and in muscarinic receptor-stimulated phosphoinositide hydrolysis have also been reported. Interestingly, neuropeptides such as neurotensin, cholecystokinin and VIP can potentiate carbachol-stimulated phosphoinositide hydrolysis in frontal cortex of both young and aged rats. This adds another level at which cholinergic neurotransmission may be modulated in senescent animals. Potential age-related differences in the effects of chronic drug treatments or experimental brain lesions on muscarinic receptor coupling to second messenger systems or on expression of mRNA for particular muscarinic receptors are currently unknown. Hence, it is possible that senescent animals may show additional deficiencies in plasticity of muscarinic receptor mediated signal transduction or expression of muscarinic receptors subtypes.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7997057     DOI: 10.1016/0024-3205(94)00378-5

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  6 in total

Review 1.  Routine deprescribing of chronic medications to combat polypharmacy.

Authors:  Doron Garfinkel; Birkan Ilhan; Gulistan Bahat
Journal:  Ther Adv Drug Saf       Date:  2015-12

2.  Ligand binding to CNS muscarinic receptor is transiently modified by convulsant 3-mercaptopropionic acid administration.

Authors:  P G Schneider; G R de Lores Arnaiz
Journal:  Neurochem Res       Date:  2000-05       Impact factor: 3.996

3.  The developing cholinergic system as target for environmental toxicants, nicotine and polychlorinated biphenyls (PCBs): implications for neurotoxicological processes in mice.

Authors:  P Eriksson; E Ankarberg; H Viberg; A Fredriksson
Journal:  Neurotox Res       Date:  2001-01       Impact factor: 3.911

4.  Cognitive toxicity of drugs used in the elderly.

Authors:  L L von Moltke; D J Greenblatt; M K Romach; E M Sellers
Journal:  Dialogues Clin Neurosci       Date:  2001-09       Impact factor: 5.986

Review 5.  Pharmacokinetic and pharmacodynamic factors that can affect sensitivity to neurotoxic sequelae in elderly individuals.

Authors:  Gary Ginsberg; Dale Hattis; Abel Russ; Babasaheb Sonawane
Journal:  Environ Health Perspect       Date:  2005-09       Impact factor: 9.031

6.  Convulsant bicuculline modifies CNS muscarinic receptor affinity.

Authors:  Patricia G Schneider; Georgina Rodríguez de Lores Arnaiz
Journal:  BMC Neurosci       Date:  2006-04-17       Impact factor: 3.288

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.